Alumis to Present at the Jefferies Global Healthcare Investor Conference
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Martin Babler, will deliver a presentation on June 4, 2025, at 3:10 p.m. ET. Interested parties can access a live webcast of the presentation through the "Investors" section of the Alumis website, under the "Events" page. The webcast recording will remain available for replay on the company's website for 90 days following the event.
Alumis Inc. (Nasdaq: ALMS), un'azienda biofarmaceutica in fase avanzata specializzata nello sviluppo di terapie mirate di nuova generazione per malattie immuno-mediate, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il Presidente e CEO della società, Martin Babler, terrà una presentazione il 4 giugno 2025 alle 15:10 ET. Gli interessati potranno seguire la diretta streaming della presentazione nella sezione "Investitori" del sito web di Alumis, alla pagina "Eventi". La registrazione del webcast sarà disponibile in replica sul sito aziendale per 90 giorni dopo l'evento.
Alumis Inc. (Nasdaq: ALMS), una empresa biofarmacéutica en etapa avanzada enfocada en desarrollar terapias dirigidas de próxima generación para enfermedades inmunomediadas, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El presidente y CEO de la compañía, Martin Babler, realizará una presentación el 4 de junio de 2025 a las 3:10 p.m. ET. Los interesados podrán acceder a la transmisión en vivo de la presentación a través de la sección "Inversores" en la página "Eventos" del sitio web de Alumis. La grabación del webcast estará disponible para reproducción durante 90 días después del evento.
Alumis Inc. (나스닥: ALMS), 면역 매개 질환을 위한 차세대 표적 치료제 개발에 주력하는 후기 단계 바이오제약 회사가 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 마틴 배블러가 2025년 6월 4일 오후 3시 10분(동부시간)에 발표를 진행할 예정입니다. 관심 있는 분들은 Alumis 웹사이트의 "투자자" 섹션 내 "이벤트" 페이지에서 라이브 웹캐스트를 시청할 수 있습니다. 웹캐스트 녹화본은 행사 종료 후 90일 동안 회사 웹사이트에서 다시보기로 제공됩니다.
Alumis Inc. (Nasdaq : ALMS), une société biopharmaceutique en phase avancée spécialisée dans le développement de thérapies ciblées de nouvelle génération pour les maladies à médiation immunitaire, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le président-directeur général de l'entreprise, Martin Babler, présentera le 4 juin 2025 à 15h10 ET. Les personnes intéressées pourront accéder à la diffusion en direct de la présentation via la section « Investisseurs » du site web d'Alumis, sous la page « Événements ». L'enregistrement du webcast restera disponible en replay sur le site de l'entreprise pendant 90 jours après l'événement.
Alumis Inc. (Nasdaq: ALMS), ein Biopharmaunternehmen in der Spätphase, das sich auf die Entwicklung von zielgerichteten Therapien der nächsten Generation für immunvermittelte Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Martin Babler, wird am 4. Juni 2025 um 15:10 Uhr ET eine Präsentation halten. Interessierte können die Live-Webcast-Präsentation über den Bereich "Investoren" auf der Alumis-Website unter der Seite "Veranstaltungen" verfolgen. Die Aufzeichnung des Webcasts wird für 90 Tage nach der Veranstaltung auf der Unternehmenswebsite zur Wiedergabe verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET.
A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Alumis Contact Information Teri Dahlman Red House Communications teri@redhousecomms.com
FAQ
When is Alumis (ALMS) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Alumis (ALMS) at the Jefferies Healthcare Conference 2025?
How can investors watch Alumis (ALMS) presentation at the Jefferies Conference?
How long will Alumis (ALMS) Jefferies Conference presentation be available for replay?
